MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ctro.2023.100587

Медицинская библиотека · Clinical and translational radiation oncology · 2023

Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.

Yegya-Raman Nikhil, Wright Christopher M, LaRiviere Michael J, Baron Jonathan A, Lee Daniel Y, Landsburg Daniel J, Svoboda Jakub, Nasta Sunita D, Gerson James N, Barta Stefan K, Chong Elise A, Schuster Stephen J, Maity Amit, Facciabene Andrea, Paydar Ima, Plastaras John P

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND PURPOSE: CD19-targeting chimeric antigen receptor T-cell (CART) therapy is a promising treatment for relapsed/refractory non-Hodgkin lymphoma, but most patients experience post-CART progression. We describe our institutional experience of salvage radiotherapy (SRT) in this setting.

MATERIALS AND

METHODS

Of 94 patients who received CART therapy from 2018 to 2020, 21 received SRT for post-CART progression. Patients were divided into two groups: locoregional disease (n = 9 [43 %], all disease encompassable within an RT field) and advanced disease (n = 12 [57 %]). Patterns of failure, progression-free survival (PFS), overall survival (OS), and toxicity were assessed.

RESULTS

Median time from CART infusion to SRT was 4.0 months (range, 0.6-11.5 months). In the locoregional disease group, 8/9 patients (89 %) were treated with comprehensive SRT to a median dose of 37.5 Gy in a median of 15 fractions. In the advanced disease group, all patients (n = 12) were treated with focal SRT to a median dose of 20.8 Gy in a median of 5 fractions. Median follow-up post-SRT was 15.2 months. In-field response was observed in 8/9 (89 %) in the locoregional disease and 8/9 (89 %) evaluable patients in the advanced disease groups. 17/18 evaluable patients (94 %) patients experienced post-SRT progression, all with a distant component. Median OS was 7.4 months; 21 months for locoregional disease versus 2.4 months for advanced disease (p = 0.0002). Median PFS was 1.1 month, and similarly poor regardless of group. No grade ≥ 3 toxicities occurred.

CONCLUSIONS

SRT post-CART therapy appears safe with encouraging in-field response but high rates of out-of-field progression, even for those presenting with locoregional disease, highlighting the need for integration of novel systemic agents.

Для цитирования: Yegya-Raman Nikhil, Wright Christopher M, LaRiviere Michael J, Baron Jonathan A, Lee Daniel Y, Landsburg Daniel J, Svoboda Jakub, Nasta Sunita D, Gerson James N, Barta Stefan K, Chong Elise A, Schuster Stephen J, Maity Amit, Facciabene Andrea, Paydar Ima, Plastaras John P. Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.. Clinical and translational radiation oncology. 2023. DOI: 10.1016/j.ctro.2023.100587.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.